These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21740573)

  • 1. Should patents for antiretrovirals be waived in the developing world? Annual Varsity Medical Debate--London, 21 January 2011.
    Corrick F; Watson R; Budhdeo S
    Philos Ethics Humanit Med; 2011 Jul; 6():13. PubMed ID: 21740573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
    Guennif S
    Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should trainee doctors use the developing world to gain clinical experience? The annual Varsity Medical Debate - London, Friday 20th January, 2012.
    Gilbert BJ; Miller C; Corrick F; Watson RA
    Philos Ethics Humanit Med; 2013 Feb; 8():1. PubMed ID: 23433035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
    Hoen E'; Berger J; Calmy A; Moon S
    J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2014 Varsity Medical Ethics Debate: should we allow genetic information to be patented?
    Metcalfe KH; Worsley CA; Swerner CB; Sinha D; Solanki R; Ravi K; Dattani RS
    Philos Ethics Humanit Med; 2015 May; 10():8. PubMed ID: 25990024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV antiretroviral agents: new threats to accessibility in developing countries].
    Nau JY
    Rev Med Suisse; 2005 Dec; 1(45):2956. PubMed ID: 16425957
    [No Abstract]   [Full Text] [Related]  

  • 9. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
    Castro A; Westerhaus M
    Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmaceutical patents and public health: challenges for the Brazilian antiretroviral treatment policy].
    Meiners CM
    Cad Saude Publica; 2008 Jul; 24(7):1467-78. PubMed ID: 18670671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Academic patents and access to medicines in developing countries.
    Sampat BN
    Am J Public Health; 2009 Jan; 99(1):9-17. PubMed ID: 19008514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should the NHS be privatized? Annual varsity medical debate - London, 22 January 2010.
    Nagendran M; Budhdeo S; Maruthappu M; Sugand K
    Philos Ethics Humanit Med; 2010 May; 5():7. PubMed ID: 20459835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 15. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?
    Attaran A; Gillespie-White L
    JAMA; 2001 Oct; 286(15):1886-92. PubMed ID: 11597292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic HIV drugs--enlightened policy for global health.
    Wainberg MA
    N Engl J Med; 2005 Feb; 352(8):747-50. PubMed ID: 15728804
    [No Abstract]   [Full Text] [Related]  

  • 19. Intellectual property rights, market competition and access to affordable antiretrovirals.
    Pascual F
    Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of activists in access to HIV and tuberculosis treatment and prevention.
    Geffen N
    Curr Opin HIV AIDS; 2017 Jul; 12(4):398-402. PubMed ID: 28463853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.